Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study
Jean-marc Ferrero
European Journal of Cancer, 2019
View PDFchevron_right
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
Piera Gargiulo
The Breast, 2017
View PDFchevron_right
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer
Alexander Macalalad
Breast Cancer: Basic and Clinical Research, 2015
View PDFchevron_right
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Jean-marc Ferrero
European journal of cancer (Oxford, England : 1990), 2018
View PDFchevron_right
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
Jean-marc Ferrero
European Journal of Cancer, 2020
View PDFchevron_right
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
M. Gnant
View PDFchevron_right
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Jérôme Lemonnier
British Journal of Cancer
View PDFchevron_right
Late lines of treatment benefit survival in metastatic breast cancer in current practice?
C. Pomel, Jean-Marc Nabholtz
The Breast, 2011
View PDFchevron_right
Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer
Ru Xin Wong
Journal of Breast Cancer, 2019
View PDFchevron_right
Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients
andrea villasco
Breast Cancer
View PDFchevron_right
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis
sofia rivera
Radiotherapy and Oncology, 2020
View PDFchevron_right
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Keyur Mehta
The Lancet, 2014
View PDFchevron_right
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Ossama Tawfik
The Lancet Oncology, 2021
View PDFchevron_right
Clinical validation of the EndoPredict test in node-positive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial
Rosalía Caballero, Lourdes Calvo
Breast Cancer Research, 2014
View PDFchevron_right
Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries
Vincent Vinh-Hung
BMC Cancer, 2004
View PDFchevron_right
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
Gunnar Aström
2013
View PDFchevron_right
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Giuseppe Tonini
Therapeutic Advances in Medical Oncology, 2021
View PDFchevron_right
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
Alexey Manikhas
BioDrugs
View PDFchevron_right
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
Jean-marc Ferrero
Therapeutic Advances in Medical Oncology, 2020
View PDFchevron_right
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database
A. Savignoni
Breast Cancer Research and Treatment, 2019
View PDFchevron_right
The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
Mary Jones
European Journal of Cancer and Clinical Oncology, 1988
View PDFchevron_right
Tailored follow-up for early breast cancer patients: A prognostic index that predicts locoregional recurrence
Marjan van Hezewijk
European Journal of Surgical Oncology (EJSO), 2010
View PDFchevron_right
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study Ã
Alberto Zaniboni
View PDFchevron_right
Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
RAUL CARTES
ecancermedicalscience
View PDFchevron_right
Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among ‘high risk’ pre- and postmenopausal breast cancer patients
Lars Rutqvist
Acta Oncologica, 2006
View PDFchevron_right
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients
M. Gnant
British journal of cancer, 2013
View PDFchevron_right
Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study
Noa Efrat
The Breast, 2017
View PDFchevron_right
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
Michinori Ogura
Cancer Science, 2007
View PDFchevron_right
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs
Naruto Taira
Breast Cancer, 2020
View PDFchevron_right
Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study
Krisztián Somlai
Croatian Medical Journal, 2016
View PDFchevron_right